These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 36428734)

  • 1. CYP1B1: A Novel Molecular Biomarker Predicts Molecular Subtype, Tumor Microenvironment, and Immune Response in 33 Cancers.
    Yuan B; Liu G; Dai Z; Wang L; Lin B; Zhang J
    Cancers (Basel); 2022 Nov; 14(22):. PubMed ID: 36428734
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Siglec-9, a Putative Immune Checkpoint Marker for Cancer Progression Across Multiple Cancer Types.
    Wu Y; Huang W; Xie Y; Wang C; Luo N; Chen Y; Wang L; Cheng Z; Gao Z; Liu S
    Front Mol Biosci; 2022; 9():743515. PubMed ID: 35372497
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
    Zhang X; Wang Y; A G; Qu C; Chen J
    Front Immunol; 2021; 12():721030. PubMed ID: 34531868
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pan-cancer genomic analyses reveal prognostic and immunogenic features of the tumor melatonergic microenvironment across 14 solid cancer types.
    Lv JW; Zheng ZQ; Wang ZX; Zhou GQ; Chen L; Mao YP; Lin AH; Reiter RJ; Ma J; Chen YP; Sun Y
    J Pineal Res; 2019 Apr; 66(3):e12557. PubMed ID: 30638277
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of SHCBP1 as a potential biomarker involving diagnosis, prognosis, and tumor immune microenvironment across multiple cancers.
    Wang N; Zhu L; Wang L; Shen Z; Huang X
    Comput Struct Biotechnol J; 2022; 20():3106-3119. PubMed ID: 35782736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A next-generation sequencing-based strategy combining microsatellite instability and tumor mutation burden for comprehensive molecular diagnosis of advanced colorectal cancer.
    Xiao J; Li W; Huang Y; Huang M; Li S; Zhai X; Zhao J; Gao C; Xie W; Qin H; Cai S; Bai Y; Lan P; Zou Y
    BMC Cancer; 2021 Mar; 21(1):282. PubMed ID: 33726687
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic Prediction, Immune Microenvironment, and Drug Resistance Value of Collagen Type I Alpha 1 Chain: From Gastrointestinal Cancers to Pan-Cancer Analysis.
    Liu Y; Xue J; Zhong M; Wang Z; Li J; Zhu Y
    Front Mol Biosci; 2021; 8():692120. PubMed ID: 34395525
    [No Abstract]   [Full Text] [Related]  

  • 8. Comprehensive analysis of the expression profile and clinical implications of regulator of chromosome condensation 2 in pan-cancers.
    Li X; Kang K; Peng Y; Shen L; Shen L; Zhou Y
    Aging (Albany NY); 2022 Nov; 14(22):9221-9242. PubMed ID: 36441563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serpin Family A Member 1 Is Prognostic and Involved in Immunological Regulation in Human Cancers.
    Kuai X; Lv J; Zhang J; Xu M; Ji J
    Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511325
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systematic Pan-Cancer Analysis Identifies TREM2 as an Immunological and Prognostic Biomarker.
    Cheng X; Wang X; Nie K; Cheng L; Zhang Z; Hu Y; Peng W
    Front Immunol; 2021; 12():646523. PubMed ID: 33679809
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The cancer-associated fibroblast-related signature predicts prognosis and indicates immune microenvironment infiltration in gastric cancer.
    Mak TK; Li X; Huang H; Wu K; Huang Z; He Y; Zhang C
    Front Immunol; 2022; 13():951214. PubMed ID: 35967313
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of ARRB1 in prognosis and immunotherapy: A Pan-Cancer analysis.
    Ye Y; Jiang H; Wu Y; Wang G; Huang Y; Sun W; Zhang M
    Front Mol Biosci; 2022; 9():1001225. PubMed ID: 36213111
    [No Abstract]   [Full Text] [Related]  

  • 13. Zic Family Member 2 (ZIC2): a Potential Diagnostic and Prognostic Biomarker for Pan-Cancer.
    Lv Z; Qi L; Hu X; Mo M; Jiang H; Fan B; Li Y
    Front Mol Biosci; 2021; 8():631067. PubMed ID: 33665207
    [No Abstract]   [Full Text] [Related]  

  • 14. The value of
    Feng Y; Wang Y; Guo K; Feng J; Shao C; Pan M; Ding P; Liu H; Duan H; Lu D; Wang Z; Zhang Y; Zhang Y; Han J; Li X; Yan X
    Ann Transl Med; 2022 Apr; 10(8):466. PubMed ID: 35571400
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pan-Cancer Analysis Revealed
    Liu J; Wang Y; Yin J; Yang Y; Geng R; Zhong Z; Ni S; Liu W; Du M; Yu H; Bai J
    J Oncol; 2022; 2022():3477148. PubMed ID: 35069733
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The prognostic and immunological effects of ZBTB7C across cancers: friend or foe?
    Chen X; Jiang Z; Wang Z; Jiang Z
    Aging (Albany NY); 2021 May; 13(9):12849-12864. PubMed ID: 33946045
    [TBL] [Abstract][Full Text] [Related]  

  • 17. POC1A, prognostic biomarker of immunosuppressive microenvironment in cancer.
    Zhao Q; Gao S; Chen X; Zhu X
    Aging (Albany NY); 2022 Jun; 14(12):5195-5210. PubMed ID: 35748773
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Wu G; Chen M; Ren H; Sha X; He M; Ren K; Qi J; Lin F
    Front Cell Dev Biol; 2022; 10():930933. PubMed ID: 35874816
    [No Abstract]   [Full Text] [Related]  

  • 19. KIF2C is a Biomarker Correlated With Prognosis and Immunosuppressive Microenvironment in Human Tumors.
    Zhang X; Li Y; Hu P; Xu L; Qiu H
    Front Genet; 2022; 13():891408. PubMed ID: 35685442
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pan-cancer analysis of CREB3L1 as biomarker in the prediction of prognosis and immunotherapeutic efficacy.
    Lin Z; Wu Y; Xiao X; Zhang X; Wan J; Zheng T; Chen H; Liu T; Tang X
    Front Genet; 2022; 13():938510. PubMed ID: 36171879
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.